FPR1 mediates the tumorigenicity of human cervical cancer cells

Guangming Cao
Zhenyu Zhang
Department of Obstetrics and Gynecology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

Purpose: The present study aimed to investigate the role of FPR1 and the downstream effectors such as NF-κB and IL-6/8 in the development of cervical cancer.

Patients and methods: FPR1 protein expression was detected via immunohistochemical staining in tissue microarrays containing cervical cancer tissues from 185 patients. Following FPR1 silencing in SiHa cells using lentiviral siRNA delivery, biological characteristics and tumor formation were evaluated in vitro and in vivo, respectively. Phosphorylated NF-κB levels were detected by Western blotting, while IL-6 and IL-8 secretion were detected by ELISA in both FPR1 knockdown and control SiHa cells. Human umbilical vein endothelial cell tube formation assays were performed to evaluate the angiogenesis-promoting ability of IL-6 and IL-8 secretion in FPR1 knockdown and control SiHa cells. Neovascularization, proliferation and apoptosis markers were detected by immunohistochemical staining to analyze the tumorigenic role of FPR1.

Results: Immunohistochemistry of cervical cancer tissues from 185 patients revealed high FPR1 expression levels in patients with advanced-stage disease and/or poor prognosis. Compared with control cells, cervical cancer cells in which FPR1 was silenced exhibited inhibition of cell invasion, migration and proliferation and higher levels of apoptosis. NF-κB was inhibited in FPR1 knockdown in SiHa cells. IL-6/8 upregulation by FPR1 activation stimulated angiogenesis. FPR1 deficiency inhibited the tumorigenicity of cervical cancer cells in nude mice. FPR1, IL-6, IL-8, CD31 and Ki67 levels were all reduced, whereas cleaved caspase-3 was upregulated, in the FPR1 knockdown group compared with the levels in the control group.

Conclusion: High FPR1 expression was associated with advanced stage and poor prognosis in cervical cancer patients. FPR1 activation induced NF-κB nuclear translocation to promote cervical cancer development through the upregulation of IL-6 and IL-8 expression. Inhibiting FPR1 activity may thus have potential therapeutic value in cervical cancer patients.

Keywords: cervical cancer, FPR1, IL-6, IL-8

Introduction

Cervical cancer is the second most common malignant tumor of the female reproductive system.1 Despite the widespread use of the Thinprep Cytology Test and HPV screening, as well as the development of treatments, cervical cancer remains one of the most common causes of cancer-related death in developing countries.2 Although early cervical cancer can be cured and has a good prognosis through surgery and/or radiation with or without chemotherapy, effective treatments for advanced, recurrent or persistent cervical cancer are lacking.3 In addition, complications and severe side
effects are not uncommon following surgery, chemotherapy and radiotherapy, which are the main treatments currently. Therefore, it is vital to find novel therapeutic targets for cervical cancer.1

FPR1 is a G-protein-coupled 7 transmembrane cell surface receptor (GPCR) involved in inflammation, wound healing and antimicrobial host defense.3,6 Accumulating evidence demonstrates that FPR1 contributes to tumor progression by mediating tumor cell chemotaxis and proliferation as well as by promoting inflammation.5,7–9 FPR1 activation has been shown to induce signaling pathways related to chronic inflammation, such as ERK, MAPK, NF-κB and STAT3, in malignant glioma cells, colon cancer and hepatocellular carcinoma cells.10–14 However, the role of FPR1 in tumorigenesis remains poorly understood, especially in cervical cancer. In the present study, immunohistochemistry (IHC) was performed on cervical cancer tissue microarrays (TMAs) to detect FPR1 expression levels. High FPR1 expression levels were detected in cervical cancer patients with advanced-stage disease and/or poor prognosis. These results suggested that FPR1 may participate in the development of cervical cancer by regulating inflammation.

Chronic inflammation is involved in the development of a wide variety of tumors.15,16 In cervical cancer patients, IL-6 and IL-8 concentrations in cervicovaginal washings are significantly higher than those in cervical intraepithelial neoplasia patients and controls.17–19 In most patients, local IL-6 and IL-8 levels were also higher in serum.18 Multiple cervical cancer cell lines have been shown to synthesize and secrete IL-6/8 in vitro.20,21 IL-6 and IL-8 are multifunctional cytokines that regulate inflammation and cancer development.20,22–24 Increasing evidence demonstrates that IL-6/8 plays a vital role in the pathogenesis of cervical cancer.

The present study aimed to investigate whether FPR1 activation can promote IL-6 and IL-8 secretion via NF-κB signaling during cervical cancer development.

**Patients and methods**

**Cell culture**

Cervical cancer cell lines (SiHa and HeLa cells) and human umbilical vein endothelial cells (HUVECs) were obtained from the Medical Research Center of Beijing Chaoyang Hospital. SiHa and HeLa cells were cultured in RPMI 1640 medium (Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% FBS (HyClone, Logan, UT, USA). HUVECs were cultured in M199 medium (Thermo Fisher Scientific) supplemented with Low Serum Growth Supplement (Thermo Fisher Scientific).

**Tissue microarray**

A total of 185 patients with cervical cancer were included in this analysis. All patients were diagnosed and managed at Beijing Chaoyang Hospital, affiliated to Capital Medical University, between January 2000 and September 2015. For each patient, H&E-stained slides were used to mark the primary tumor location. One tissue cylinder (1 mm diameter) per sample was obtained and transferred into a recipient paraffin block using a manual tissue arrayer.

Five micrometer sections of TMA blocks were dewaxed in xylol for 15 minutes, rehydrated using graded alcohol and finally washed using PBS. Sections were incubated in 3% H2O2 (diluted in methyl alcohol) for 30 minutes to inhibit endogenous peroxidase. Antigen retrieval was performed by microwaving samples in citric acid buffer (pH 6.0). Then, sections were incubated with 5% BSA (w/v) for 1 hour at room temperature. TMA sections were incubated overnight at 4°C with rabbit anti-FPR1 (Abcam, MA, USA) antibody diluent in 5% BSA (w/v). Incubation with secondary antibody was performed using HRP-labeled goat anti-rabbit antibody for 1 hour at room temperature, followed by treatment with 500 µL DAB for 1 minute. Sections were stained with H&E for 30 seconds and then dehydrated and mounted according to the standard operating procedures. Staining scores were calculated using Image Pro Plus 6.0.

\[ H\text{-SCORE} = \sum (PI \times I) = (\text{percentage of cells of weak intensity} \times 1) + (\text{percentage of cells of moderate intensity} \times 2) + (\text{percentage of cells of strong intensity} \times 3) \]

Silencing of FPR1 expression in SiHa cells by siRNA technology was used to knock down FPR1 in vitro. siRNAs against FPR1 and corresponding scrambled siRNAs (GenePharma, Shanghai, China) were transfected into SiHa cells using Lipofectamine 2000 (Thermo Fisher Scientific) for 48 hours. The following siRNA sequences were used: siFPR1, sense: 5′-CCTGCATATCATCTTATTT-3′, antisense: 5′-ATAAGTGATGATATGCAGGTT-3′.

**Flow cytometry analysis**

For apoptosis analysis, cells were stained with propidium iodide (PI) and Annexin V–phycocerythrin for 15 minutes at room temperature in the dark and then analyzed on a FACSCalibur Flow Cytometer (BD Biosciences, San Jose, CA, USA). For cell cycle analysis, cells were stained with PI for 45 minutes at room temperature in the dark and then analyzed on a FACSCalibur Flow Cytometer.
Production of lentiviral particles
Two groups of fragments, separately containing FPR1 shRNA (GCTATCTTTCTGGATAT) and control (scramble shRNA; TTCTCCAGACGTTCACGT), were cloned into the GV248 plasmid (Genechem Co., Ltd, Shanghai, China). Then, GV248 was cotransfected with other packaging plasmids into HEK293T cells using Lipofectamine 2000, and viral particles were collected 48 hours after transfection.

FPR1 stable knockdown in SiHa cells
For knockdown assays, SiHa cells were infected with a lentiviral vector carrying FPR1 shRNA or the scrambled sequence at an MOI of 30. After 72 hours of infection, cells infected with lentiviral vectors encoding enhanced green fluorescent protein (eGFP) were observed via fluorescence microscopy to assess transduction efficiency and eGFP expression. Cells with 80% infection efficiency and better proliferative ability were selected and expanded through puromycin treatment. The efficiency of silencing and amplification of FPR1 was confirmed by reverse transcription PCR (RT-PCR).

RNA extraction and reverse transcription PCR
Total RNA was extracted from cells or placental tissues using TRIzol (Thermo Fisher Scientific) following the manufacturer's instruction. Reverse transcription was performed with 2 µg of RNA using a PrimeScript RT reagent kit with gDNA eraser (Takara Bio Inc., Dalian, China). RT-PCR was performed on a Roche Light Cycler 480 II detection system (Hoffman-La Roche Ltd., Basel, Switzerland). cDNA detection was carried out following the instructions of the SYBR® Premix Ex Taq™ kit (Takara Bio Inc., Dalian, China). RT-PCR was performed on a Roche Light Cycler 480 II detection system (Hoffman-La Roche Ltd., Basel, Switzerland). cDNA detection was carried out following the instructions of the SYBR® Premix Ex Taq™ kit (Takara Bio Inc.). RT-PCR was performed on a Roche Light Cycler 480 II detection system (Hoffman-La Roche Ltd., Basel, Switzerland). cDNA detection was carried out following the instructions of the SYBR® Premix Ex Taq™ kit (Takara Bio Inc.).

Western blotting
Nuclear and cytoplasmic proteins were extracted following the manufacturer's instructions using the Cytoplasm protein/Nucleoprotein extraction kit (Beyotime Institute of Biotechnology, Haimen, China). Equal amounts (30 µg) of cellular extracts were separated via 10% SDS-PAGE. Proteins were transferred to nitrocellulose membranes (EMD Millipore, Billerica, MA, USA) and incubated overnight with specific antibodies, followed by incubation with specific HRP-conjugated secondary antibodies. Films were scanned using a calibrated Bio-Rad GS 800 densitometer, and signals were analyzed using ImageJ. FPR1, GAPDH, NF-xB p65, p-NF-xB p65 and Lamin B antibodies were obtained from Abcam.

IHC analysis
After the experiments ended, tumor tissues were isolated and fixed in paraformaldehyde for 24 hours. Paraffin-embedded sections were stained with H&E. The FPR1, IL-6, IL-8, CD31 and Ki67 monoclonal antibodies (Abcam) were used as the secondary antibody, and staining was performed with a solution containing DAB.

Measurement of IL-6/8 in conditioned medium by ELISA assay
Cells were plated at 5×10⁴ cells/well in a six-well plate, and cell culture supernatants were collected after 48 hours of culture. Then, IL-6 and IL-8 concentrations were measured using ELISA kits according to the manufacturer's instructions (Thermo Fisher Scientific, Waltham, MA, USA).

Transwell invasion assays
Invasion assays were conducted in 24-well fitted inserts with membranes (8-µm pore size; Costar, Cambridge, MA, USA) as reported previously. SiHa cells were trypsinized and seeded into transwell inserts precoated with 40 µg/mL Matrigel (BD Biosciences) at 5×10⁴ cells per insert. The top chambers contained RPMI 1640 medium supplemented with 0.1% FBS, and the lower chambers were loaded with RPMI 1640 medium plus 10% FBS. After incubation for 30 hours, the cells were fixed and stained with crystal violet. Cells on
the upper surface of the membrane were completely removed, and the number of stained cells at the lower surface of the membrane was counted on a light microscope.

**Wound-healing assays**
A total of $3 \times 10^6$ SiHa cells were mixed and plated in six-well plates. When the cells reached 80% confluence, a 200 µL pipette tip was used to scratch and create a gap in the monolayer. N-formyl-methionyl-leucyl-phenylalanine (fMLF) (Sigma-Aldrich Co., St Louis, MO, USA) was added to the medium at the indicated concentrations. Cell movement phase images were subsequently captured via light microscopy every 8 hours. ImageJ software was used to analyze the mean migrated distance of the leading cells in the scratched area (gate).

**Xenografts**
SiHa cells were trypsinized, washed twice and resuspended in ice-cold PBS. Four-week-old female BALB/c nude mice were injected with $3 \times 10^6$ cells in 100 mL PBS. Tumor volumes were calculated according to the following formula: $V = 0.5 \times D \times d \times d$, where $D$ represents length and $d$ represents the width of tumors measured by a digital caliper. Mice were sacrificed by CO$_2$, and tumors were isolated and further processed. Animal care was provided in accordance with the Guide for the Care and Use of Laboratory Animals.

**Statistical analyses**
SPSS version 22.0 (IBM Corporation, Armonk, NY, USA) was used for the statistical analyses. All quantitative data were expressed as mean±SD. Independent-samples $t$-tests were used for comparisons of variables between groups. Correlations between the detected markers were assessed using Spearman’s rank correlation. $P$-values of $<0.05$ were considered statistically significant.

**Ethics statement**
The present study was approved by the ethics committee of Beijing Chaoyang Hospital, affiliated to Capital Medical University. All patients whose tissues were used in this study provided written informed consent in accordance with the Declaration of Helsinki. Study protocols were carried out in accordance with approved guidelines. All animal studies were carried out in accordance with the recommendations in the Guide for the Management Ordinance of Laboratory Animals of the Society of Laboratory Animals. Experimental protocols were approved by Beijing Chaoyang Hospital, affiliated to Capital Medical University. All surgical procedures were performed under anesthesia, and every effort was made to minimize suffering.

**Results**

**FPR1 expression in human cervical cancer tissues**
We performed TMA analysis to establish the relationship between FPR1 expression levels in cervical cancer tissues and different pathological stages. Table 1 summarizes the clinical characteristics of the 185 cervical cancer patients involved in this study. According to the cervical cancer guide from the National Comprehensive Cancer Network, advanced-stage cervical cancer includes patients from stage IIB to IVA. We therefore divided the patients in this study into two groups: advanced stage (IIB–IVA) and early stage (I–IIA). Advanced-stage cervical cancer patients had significantly higher FPR1 staining H-scores than early stage cervical cancer patients ($P<0.001$; Table 2). Next, we compared FPR1 expression levels among cervical cancer patients with different overall

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Clinical characteristics of patients involved in this study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics</td>
<td>No. of patients</td>
</tr>
<tr>
<td>Age, years</td>
<td></td>
</tr>
<tr>
<td>≤40</td>
<td>60</td>
</tr>
<tr>
<td>41–50</td>
<td>74</td>
</tr>
<tr>
<td>51–60</td>
<td>34</td>
</tr>
<tr>
<td>61–70</td>
<td>14</td>
</tr>
<tr>
<td>&gt;70</td>
<td>3</td>
</tr>
<tr>
<td>Preoperative chemotherapy</td>
<td></td>
</tr>
<tr>
<td>Yes</td>
<td>70</td>
</tr>
<tr>
<td>No</td>
<td>115</td>
</tr>
<tr>
<td>Pathological stage</td>
<td></td>
</tr>
<tr>
<td>I–IIA</td>
<td>129</td>
</tr>
<tr>
<td>IIB–IVA</td>
<td>56</td>
</tr>
<tr>
<td>Lymphatic metastasis</td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>155</td>
</tr>
<tr>
<td>Yes</td>
<td>30</td>
</tr>
<tr>
<td>Differentiation level</td>
<td></td>
</tr>
<tr>
<td>High</td>
<td>59</td>
</tr>
<tr>
<td>Middle</td>
<td>55</td>
</tr>
<tr>
<td>Low</td>
<td>71</td>
</tr>
<tr>
<td>OS</td>
<td></td>
</tr>
<tr>
<td>OS ≤5</td>
<td>20</td>
</tr>
<tr>
<td>OS ≥5</td>
<td>165</td>
</tr>
</tbody>
</table>

**Table 2** FPR1 staining H-score in advanced-stage cancer patients is significantly higher than that in early stage cervical cancer patients

<table>
<thead>
<tr>
<th>Pathological stage</th>
<th>I–IIA</th>
<th>IIB–IVA</th>
<th>$P$-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>N=129</td>
<td>N=56</td>
<td></td>
</tr>
<tr>
<td>FPR1</td>
<td>$130.8±34.2$</td>
<td>$209.6±31.7$</td>
<td>$&lt;0.001$</td>
</tr>
</tbody>
</table>

**Note:** Two-sample rank-sum test using SPSS 22.0.
survival times. The data demonstrated that high FPR1 expression levels are related to poor prognosis (\(P<0.001; \) Table 3).

**FPR1 protein and mRNA expression in human cervical cancer cell lines**

To explore the biological function of FPR1 in cervical cancer development, two established human cervical cancer cell lines, SiHa and HeLa, were used in our experiments. Western blotting (Figure 1A and B) and RT-PCR (Figure 1C) showed that both SiHa and HeLa cells expressed FPR1, with SiHa cells expressing higher levels of FPR1 than HeLa cells (\(P<0.01\)).

**FPR1 promotes human cervical cancer cell invasion, migration and proliferation**

We chose SiHa cells to test the biological function of FPR1 in human cervical cancer cells. First, we designed siRNA oligos to silence FPR1 expression in SiHa cells. As shown in Figure 2A and B, compared with control siRNA, the specific siRNA suppressed FPR1 expression in SiHa cells (\(P<0.01\)). Next, we transfected si-FPR1 oligos into SiHa cells to explore the role of FPR1. Silencing of FPR1 expression using specific siRNAs resulted in the inhibition of cell invasion (\(P<0.01\)), especially under fMLF treatment, which is a typical FPR1 agonist (\(P<0.01; \) Figure 2C and D).

To more precisely examine the contribution of FPR1 to cervical cancer cell motility and invasiveness, we used a wound-healing model by creating a gap in a confluent SiHa cell monolayer. Silencing of FPR1 expression inhibited cell migration (\(P<0.01; \) Figure 2E and F). Thus, FPR1 activation promoted cell migration. SiHa cells treated with fMLF showed more rapid migration than vehicle-treated cells toward the center of the gap in the cell monolayer. These data demonstrated that FPR1 regulated cervical cancer cell motility.

Next, to further verify the role of FPR1 in human cervical cancers, we detected epithelial–mesenchymal transition (EMT)-related proteins and transcription factors in FPR1-silenced SiHa cells. FPR1 silencing inhibited Vimentin (\(P<0.05\)) and MMP9 (\(P<0.05\)) expression (Figure 2G) but promoted E-cadherin (\(P<0.05\)) and \(\beta\)-catenin expression (\(P<0.05; \) Figure 2G). FPR1 also inhibited the expression of the transcription factors such as Twist (\(P<0.05\)) and Snail (\(P<0.05; \) Figure 2H). Thus, silencing of FPR1 inhibited SiHa cell EMT program. Overall, we demonstrated that FPR1 promotes cervical cancer cell malignant phenotypes, which matches the poor prognosis in cervical cancer patients and cell functional assays.

![Figure 1](https://www.dovepress.com/)

**Figure 1** The expression of FPR1 protein and mRNA in human cervical cancer cell lines.

**Notes:** (A, B) Western blot showing the relative FPR1 expression levels in HeLa and SiHa cells. (C) RT-PCR showing the relative FPR1 expression levels in HeLa and SiHa cells. Bar chart according to the statistical analysis based on the results of three independent experiments. Data are expressed as mean±SEM. *\(P<0.05\).

**Abbreviations:** RT-PCR, reverse transcription PCR; SEM, standard error of the mean.

**Table 3 High FPR1 staining H-score indicates poor prognosis**

<table>
<thead>
<tr>
<th>No. of patients</th>
<th>OS &lt;5 years</th>
<th>OS ≥5 years</th>
<th>(P)-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>FRP1</td>
<td>N=20</td>
<td>N=165</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>142.2±39.6</td>
<td>169.0±41.7</td>
<td></td>
</tr>
</tbody>
</table>

*Two-sample rank-sum test using SPSS 22.0.

**FPR1 mediates NF-κB activation in cervical cancer cells**

Since FPR1 is a typical GPCR involved in many signaling pathways, especially inflammatory signaling, we stimulated serum-starved SiHa cells with 100 nM fMLF and tested NF-κB activation in cells with or without FPR1 knockdown. FPR1 knockdown inhibited NF-κB phosphorylation, suggesting that fMLF promotes NF-κB phosphorylation through FPR1 (Figure 3A). Further analysis showed that FPR1 silencing decreased NF-κB subunit P65 expression in the nucleus.
Figure 2: Knockdown of FPR1 represses SiHa cell invasion and migration.

Notes: (A, B) Western blot showing FPR1 expression levels in SiHa cells transiently transfected with siRNA against FPR1 (si-FPR1) or scrambled siRNA (si-NC). (C, D) Transwell invasion assays in SiHa cells upon FPR1 knockdown in response to 100 nM fMLF. The magnification is 200×. (E, F) Wound-healing cell migration assay in SiHa cells following FPR1 knockdown in response to 100 nM fMLF. (G) Expression levels of the EMT-related molecules such as E-cadherin, β-catenin, Vimentin and MMP9 were determined by RT-PCR. (H) mRNA levels of the EMT-related transcription factors such as Snail and Twist were determined by RT-PCR. (I, J) FACS analysis of apoptosis in SiHa cells with FPR1 knockdown. (K, L) FACS analysis of the cell cycle in SiHa cells with FPR1 knockdown. Bar chart according to the statistical analysis based on the result of three independent experiments. Data are expressed as mean±SEM. *P<0.05.

Abbreviations: EMT, epithelial-mesenchymal transition; fMLF, N-formyl-methionyl-leucyl-phenylalanine; RT-PCR, reverse transcription PCR; SEM, standard error of the mean.
and increased P65 expression in the cytoplasm (Figure 3A). In addition, the phosphorylated (ie, active) P65 levels were reduced in FPR1-silenced SiHa cells (Figure 3A). These results suggested that the nuclear translocation and activation of P65 were inhibited in FPR1-silenced SiHa cells.

**FPR1 activation enhances angiogenesis by promoting IL-6 and IL-8 production**

Then, we examined the inflammatory factors such as IL-6 and IL-8 in human cervical cancer cells. FPR1 knockdown inhibited IL-6 and IL-8 secretion, particularly upon treatment with fMLF (Figure 3B and E). Furthermore, because IL-6 and IL-8 can promote angiogenesis in many tumors, we next used HUVEC tube formation assays to evaluate FPR1 function in angiogenesis. We collected cell culture supernatants from SiHa cells with or without FPR1 knockdown, followed by incubation with anti-IL-6 or anti-IL-8 antibody. The experiments showed that angiogenesis was inhibited by the addition of a monoclonal antibody against human IL-6/8. Thus, IL-6 and IL-8 in conditioned supernatants from FPR1-activated SiHa cells induce endothelial cells to form capillary-like structures, which is important in tumorigenesis (Figure 3C, D, F and G).

**FPR1 promotes cervical cancer development**

We used a lentivirus–shRNA system to induce FPR1 knockdown in SiHa cells, with lentivirus–shScramble RNA-infected SiHa cells serving as a control group. FPR1 mRNA expression level was stably repressed in the knockdown cells (Figure 4A and B). To investigate the function of FPR1 in cell proliferation, Cell Counting Kit-8 assays were then carried out. FPR1 deficiency inhibited SiHa cell proliferation (Figure 4C).

To assess the role of FPR1 in cervical cancer development in vivo, two groups of nude mice, with 10 animals in each group, were injected with lentivirus FPR1 knockdown and control cells into the subcutaneous tissue in the upper back, and tumor size was monitored every 5 days. Tests were terminated, and tumor sampling was performed when the tumor size in control animals reached a volume of 0.5–1 cm$^3$. Compared with the control group, FPR1 knockdown in SiHa cells exhibited suppressed tumor formation ability (Figure 4D and E). The tumor growth rate of the FPR1 deficiency group was significantly lower than that of the normal control group (Figure 4E). Thus, FPR1 promotes cervical cancer development.

---

**Figure 3** FPR1 mediated NF-κB activation and IL-6/8 production by SiHa cells.

**Notes:** (A) Effects of FPR1 knockdown on the nuclear translocation and activation of P65. NF-κB expression in SiHa cells stimulated with 100 nM fMLF for 20 minutes was examined by Western blotting. (B, E) IL-6 and IL-8 levels in the supernatants of SiHa cells treated with 100 nM fMLF, as measured by ELISA. (C, D) HUVEC tube formation assays on Matrigel. Culture supernatants from SiHa cells treated with 100 nM fMLF for 48 hours were incubated with anti-IL-6 antibody (C) or IgG (–) (each at 1 mg/ml) for 2 hours. HUVECs were then mixed with the supernatants and examined for tubule formation on Matrigel after 4 hours. (F, G) Culture supernatants from SiHa cells treated with 100 nM fMLF for 48 hours were incubated with an anti-IL-8 antibody (C) or IgG (–) (each at 1 mg/ml) for 2 hours. HUVECs were then mixed with the supernatants and examined for tubule formation on Matrigel after 4 hours. Bar chart according to the statistical analysis based on the result of three independent experiments. Data are expressed as mean±SEM. *P<0.05.

**Abbreviations:** fMLF, N-formyl-methionyl-leucyl-phenylalanine; HUVECs, human umbilical vein endothelial cells; SEM, standard error of the mean.
**Figure 4** The effect of FPR1 knockdown on SiHa cell tumorigenicity in nude mice.

**Notes:**
(A) Construction of SiHa cells with stable FPR1 knockdown using a lentivirus–shRNA system. The magnification is 200×. (B) RT-PCR showing the relative expression levels of FPR1 mRNA in SiHa cells stably transfected with FPR1 lentivirus–shFPR1; lentivirus–shScramble was used as a control. (C) Growth curves of shRNA-transfected SiHa cells. Cell growth was measured using CCK-8 assays. (D, E) Tumor formation assays. SiHa cells were injected subcutaneously into the upper back of nude mice (10 mice per group). Mice were examined for tumor formation every 5 days. (F) IHC staining showing FPR1, IL-6 and IL-8 expression in tumor tissue. The magnification is 200×. (G) H&E and IHC staining of tumor structure. The vascular epithelial cell marker CD31, the ubiquitous cell cycle marker Ki67 and the apoptosis marker cleaved caspase-3 were stained to evaluate neovascularization, proliferation, and apoptosis, respectively, in tumor tissue. (H–J) Bar chart showing the area of neovascularization in tumor tissue and the numbers of Ki67-positive and cleaved caspase-3-positive cells. Data are expressed as mean±SEM. *P<0.05.

**Abbreviations:** CCK-8, Cell Counting Kit-8; IHC, immunohistochemistry; RT-PCR, reverse transcription PCR; SEM, standard error of the mean.
Following these experiments, tumor tissues were isolated and fixed for histological analysis to detect for FPR1, IL-6 and IL-8 expression levels (Figure 4F). As expected, IL-6 and IL-8 expressions were repressed in FPR1-deficient cells. We clearly observed fewer blood cells in tumors from the FPR1 knockdown group than in the control group by H&E staining (Figure 4G). To further verify the role of FPR1 in angiogenesis, we used the epithelial cell marker CD31 to indicate blood vessels in the tumor. The blood vessel area was significantly lower in the FPR1 knockdown cells than in the control group (P<0.01). Thus, FPR1 deficiency inhibited tumor angiogenesis (Figure 4G and H). This finding is consistent with the results of our in vitro experiments.

To understand whether FPR1 has any effect on tumor formation, we analyzed the proliferation and apoptosis ability of tumors with FRP1 knockdown. For this purpose, we stained cells for the ubiquitous cell cycle marker Ki67 and apoptosis marker cleaved caspase-3. IHC analysis revealed lower numbers of Ki67+ nuclei in FPR1 knockdown tumors than in the control group (Figure 4G and I), whereas the number of cleaved caspase-3+ cells increased significantly in the FPR1 knockdown group, indicating that FPR1 inhibits apoptosis in cervical cancer cells (Figure 4G and J).

Discussion
FPR1 is reported to be overexpressed in a wide variety of tumors and to be involved in cancer progression.7,8,25,26 Database analyses revealed that FPR1 expression levels are upregulated in malignant glioma cells, colon cancer, lung cancer and hepatocellular carcinoma cells compared with those in normal controls.27–30 According to our results, FPR1 was also overexpressed in tumor tissues from terminal-stage cervical cancer patients and from patients with poor prognosis. These observations indicated that FPR1 expression levels may serve as a diagnostic marker for cervical cancer. Furthermore, FPR1 silencing inhibited cervical cancer cell tumor features such as invasion and migration, suggesting that high FPR1 expression may facilitate cervical cancer development and also explaining the link between high FPR1 levels and poor prognoses in cervical cancer patients. These findings demonstrate a potentially important role for FPR1 in the diagnosis and prognosis of cervical cancer patients. We therefore hypothesized that FPR1 may function as an oncogene involved in the tumorigenesis and progression of cervical cancer. To test this hypothesis, we performed a series of in vitro and in vivo assays. Our results showed that knocking down FPR1 inhibited malignant phenotypes such as proliferation, EMT, migration and invasion. These data suggested that FPR1 is indeed an oncogene that plays a vital role in cervical cancer progression.

FPR1 localizes to the surface and can be activated by Anx-A1 secreted by cancer cells and normal cells. Activated FPR1 induces the activation of a series of regulatory molecules, including p38, MAPK and ERK1/2, as well as many transcription factors, such as NF-κB, STAT3 and HIF-1α, to promote cancer cell proliferation, invasion and migration.11,13,31,32 All the data demonstrate that FPR1 agonists within tumor cell microenvironment induce several vital signaling pathways that promote tumorigenesis. We focused on the activation of NF-κB translocation into the cell nucleus to regulate the synthesis and secretion of inflammatory factors. Our results showed that FPR1-activated NF-κB signaling pathways involved in cervical cancer development.

We then examined the expression levels of the typical inflammatory factors such as IL-6 and IL-8. IL-6 and IL-8 are known to be directly implicated in the onset of a wide variety of tumors and are considered to be tumor growth factors.33,34 IL-6 and IL-8 expression levels are significantly elevated in tissues from numerous cancers compared with those in healthy adjacent tissues.35–37 IL-6 and IL-8 are also involved in cervical cancer progression, which is consistent with our results. The role of inflammatory responses in tumorigenesis is very complicated. IL-6 also plays an important role in the proliferation and apoptosis of tumor cells. IL-6 binds to GP130 to activate various signal transduction pathways. IL-6/STAT3 activation is involved in cell apoptosis (Bcl-2), angiogenesis (VEGF), cell invasion and migration (MMP2/9) and particularly cell inflammation (IL-17).24,38,39

Our experiments showed that IL-6 and IL-8 expression levels in cervical cancer cells are regulated by FPR1-related signaling. Thus, cervical cancer tissues produce large quantities of IL-6 and IL-8 that can induce reactions throughout the body, especially in the local cancer microenvironment. Both IL-6 and IL-8 perform multiple functions in the onset and development of cancer. IL-6 upregulation in the cervical cancer microenvironment can induce cancer cell proliferation and invasion and promote angiogenesis in tumor tissue. IL-8 is upregulated in cervical cancer tissues and is associated with cervical cancer cell proliferation and migration. These findings demonstrate that IL-6 and IL-8 play a vital role in cervical cancer progression. Nevertheless, the specific role of IL-6 and IL-8 in the pathogenesis of cervical cancer remains elusive. IL-6 and IL-8 generally thought to induce VEGF expression in angiogenesis, and our results indicated that IL-6 and IL-8 may facilitate the development of cervical cancer by modulating tumor angiogenesis.
Conclusion
High FPR1 expression levels were associated with advanced stage and poor prognosis in cervical cancer patients. FPR1 activation induced NF-κB nuclear translocation and promoted the development of cervical cancer by upregulating IL-6 and IL-8 expression levels. Inhibition of FPR1 activity may therefore have potential therapeutic value in patients with cervical cancer.

Acknowledgment
This study was supported in part by the Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support and 2012DFR30490 (ZZ).

Disclosure
The authors report no conflicts of interest in this work.

References